Alanine prevents the decrease of Na+,K+-ATPase activity in experimental phenylketonuria.
Our objective was to investigate the effect of alanine administration on Na+,K+-ATPase activity in cerebral cortex of rats subjected to chemically-induced phenylketonuria. Wistar rats were treated from the 6th to the 28th day of life with subcutaneous injections of either 2.6 micromol alanine or 5.2 micromol phenylalanine plus 2.6 micromol alpha-methylphenylalanine per g body weight or phenylalanine plus alpha-methylphenylalanine plus alanine in the same doses or equivalent volumes of 0.15 M saline. The animals were killed on the 29th or 60th day of life. Synaptic plasma membrane from cerebral cortex was prepared for Na+,K+-ATPase activity determination. The results showed that alanine injection prevents the decrease of Na+,K+-ATPase activity in animals subjected to experimental phenylketonuria. Therefore, in case the same effects are achieved with ingested alanine, it is possible that alanine supplementation may be an important dietary adjuvant for phenylketonuric patients.
Wyse
A T
AT
Departamento de Bioquímica, ICBS, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Noriler
M E
ME
Borges
L F
LF
Floriano
P J
PJ
Silva
C G
CG
Wajner
M
M
Wannmacher
C M
CM
D000409:Alanine / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn; D002540:Cerebral Cortex / Q000201:enzymology*; D007279:Injections, Subcutaneous; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000494:pharmacology; D010661:Phenylketonurias / Q000201:enzymology*; D051381:Rats; D017208:Rats, Wistar; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism*
C012436:alpha-methylphenylalanine; D010649:Phenylalanine; D000254:Sodium-Potassium-Exchanging ATPase; D000409:Alanine